Brokerages Set Luminex Co. (LMNX) Price Target at $27.00

Share on StockTwits

Shares of Luminex Co. (NASDAQ:LMNX) have earned an average recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $27.00.

Several analysts recently issued reports on LMNX shares. BidaskClub lowered shares of Luminex from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. Citigroup dropped their price target on shares of Luminex from $34.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, November 6th. ValuEngine upgraded shares of Luminex from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 29th. TheStreet lowered shares of Luminex from a “b-” rating to a “c+” rating in a research report on Friday, December 14th. Finally, Zacks Investment Research upgraded shares of Luminex from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th.

Shares of NASDAQ LMNX opened at $24.98 on Friday. The company has a market cap of $1.11 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 3.07 and a beta of 0.67. Luminex has a 12-month low of $18.62 and a 12-month high of $35.37.

Luminex (NASDAQ:LMNX) last announced its earnings results on Monday, November 5th. The medical instruments supplier reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.03). The business had revenue of $72.40 million for the quarter, compared to the consensus estimate of $74.05 million. Luminex had a net margin of 5.65% and a return on equity of 5.99%. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.13 earnings per share. On average, equities analysts predict that Luminex will post 0.58 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, January 10th. Investors of record on Thursday, December 20th were given a dividend of $0.06 per share. The ex-dividend date was Wednesday, December 19th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.96%. Luminex’s dividend payout ratio is 26.37%.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its position in shares of Luminex by 0.8% during the third quarter. BlackRock Inc. now owns 6,644,013 shares of the medical instruments supplier’s stock worth $201,379,000 after acquiring an additional 50,973 shares during the last quarter. Vanguard Group Inc raised its stake in Luminex by 4.8% during the third quarter. Vanguard Group Inc now owns 4,268,240 shares of the medical instruments supplier’s stock valued at $129,370,000 after purchasing an additional 194,226 shares in the last quarter. Vanguard Group Inc. raised its stake in Luminex by 4.8% during the third quarter. Vanguard Group Inc. now owns 4,268,240 shares of the medical instruments supplier’s stock valued at $129,370,000 after purchasing an additional 194,226 shares in the last quarter. Acadian Asset Management LLC raised its stake in Luminex by 3.7% during the third quarter. Acadian Asset Management LLC now owns 1,635,083 shares of the medical instruments supplier’s stock valued at $49,560,000 after purchasing an additional 58,487 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Luminex by 1.3% during the second quarter. Northern Trust Corp now owns 967,694 shares of the medical instruments supplier’s stock valued at $28,575,000 after purchasing an additional 12,587 shares in the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Read More: How do taxes affect a CDs total return?

Analyst Recommendations for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply